Analysts predict that Edwards Lifesciences Corp (NYSE:EW) will post earnings of $1.11 per share for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Edwards Lifesciences’ earnings, with estimates ranging from $1.05 to $1.14. Edwards Lifesciences posted earnings of $0.94 per share during the same quarter last year, which would suggest a positive year over year growth rate of 18.1%. The firm is expected to report its next quarterly earnings results after the market closes on Tuesday, April 24th.
On average, analysts expect that Edwards Lifesciences will report full-year earnings of $4.53 per share for the current financial year, with EPS estimates ranging from $4.48 to $4.58. For the next financial year, analysts forecast that the company will report earnings of $5.07 per share, with EPS estimates ranging from $4.78 to $5.25. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. During the same quarter in the prior year, the business posted $0.75 EPS. The firm’s revenue was up 15.7% compared to the same quarter last year.
A number of equities research analysts have issued reports on EW shares. Evercore ISI started coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price objective for the company. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, April 10th. Finally, Cowen reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, March 20th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $145.92.
EW stock traded up $0.28 during trading on Monday, reaching $138.12. The stock had a trading volume of 1,481,403 shares, compared to its average volume of 1,332,024. Edwards Lifesciences has a one year low of $93.67 and a one year high of $143.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80. The company has a market capitalization of $28,949.67, a price-to-earnings ratio of 36.35, a PEG ratio of 2.02 and a beta of 0.57.
In other news, VP Huimin Wang sold 3,800 shares of the stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $141.84, for a total transaction of $538,992.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $126.69, for a total transaction of $4,155,432.00. Following the transaction, the chief executive officer now directly owns 74,131 shares of the company’s stock, valued at $9,391,656.39. The disclosure for this sale can be found here. Insiders have sold a total of 197,236 shares of company stock valued at $26,375,070 over the last three months. Insiders own 1.84% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $128,000. Resources Investment Advisors Inc. lifted its stake in shares of Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after buying an additional 465 shares in the last quarter. Exane Derivatives lifted its stake in shares of Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after buying an additional 961 shares in the last quarter. Lake Street Advisors Group LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $201,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $204,000. 82.98% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://macondaily.com/2018/04/16/analysts-anticipate-edwards-lifesciences-corp-ew-will-announce-earnings-of-1-11-per-share.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Get a free copy of the Zacks research report on Edwards Lifesciences (EW)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.